[Value of radiotherapy in disseminated highly malignant non-Hodgkin's lymphoma. Comment on the article by U. Kaiser, R. Pfab, K. Havemann, Strahlenther Onkol 1997, 173, 136-40 (No. 3)].
Stuschke
M
M
Nowrousian
M R
MR
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant; D009626:Terminology as Topic; D013997:Time Factors; D014750:Vincristine / Q000627:therapeutic use
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
Stellenwert der Strahlentherapie beim disseminierten hochmalignen Non-Hodgkin-Lymphom. Zu dem Beitrag von U. Kaiser, R. Pfab, K. Havemann: Strahlenther Onkol 1997;173;136-40 (Nr. 3).